CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 5,025 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00524537
NCT00524537N/ACompleted
CompareCT.gov

A Long-Term Non-Interventional Registry to Assess Safety and Effectiveness of HUMIRA® (Adalimumab) in Subjects With Moderately to Severely Active Crohn's Disease (CD)

AbbVie (prior sponsor, Abbott)·observational·Posted Sep 3, 2007·Updated Jan 24, 2017

In Brief

An observational study for Crohn's Disease. Completed, enrolled 5,025 participants.

Detailed Summary

The purpose of this Registry study is to evaluate the long-term safety and effectiveness of adalimumab in CD subjects who are treated as recommended in the product label.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsCrohn's Disease
Countries--
Collaborators--

Timeline

N/ACompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 3, 2007
Enrollment StartSep 1, 2007
Primary CompletionDec 1, 2015
TodayJul 2, 2026
Enrollment to primary: 8.3 yearsPosted 18.8 years ago